Financial Performance - The company's operating revenue for the first half of 2024 was CNY 319.32 million, a decrease of 8.82% compared to CNY 350.21 million in the same period last year[13]. - The net profit attributable to shareholders for the first half of 2024 was a loss of CNY 15.76 million, a significant decrease of 1,226.26% compared to a profit of CNY 1.40 million in the previous year[13]. - The net cash flow from operating activities was a negative CNY 51.34 million, down 561.07% from a positive CNY 11.13 million in the same period last year[13]. - The total assets at the end of the reporting period were CNY 1.58 billion, representing a decrease of 12.06% from CNY 1.80 billion at the end of the previous year[13]. - The net assets attributable to shareholders decreased by 2.81% to CNY 782.17 million from CNY 804.80 million at the end of the previous year[13]. - Basic and diluted earnings per share for the first half of 2024 were both -CNY 0.023, a decrease of 1,250.00% compared to CNY 0.002 in the same period last year[14]. - The weighted average return on net assets was -1.98%, a decrease of 2.15 percentage points compared to 0.17% in the previous year[14]. - The company reported a significant decline in net profit primarily due to reduced performance from subsidiaries Shanghai Fudan Forward Pharmaceutical Co., Ltd. and Shanghai Zhonghe Software Co., Ltd.[15]. - The company did not propose any profit distribution plan or capital reserve transfer to share capital for the reporting period[3]. - The company reported non-recurring gains totaling RMB 5,092,986.59, with significant contributions from government subsidies and other non-operating income[16]. Industry Overview - The pharmaceutical sector's revenue for the first half of 2024 was RMB 12,352.7 billion, showing a year-on-year decline of 0.9%[17]. - The overall profit margin for the pharmaceutical manufacturing industry increased by 0.7% year-on-year, reaching a total profit of RMB 1,805.9 billion[17]. - The retail sales of traditional Chinese and Western medicines grew by 4.4% year-on-year, reaching RMB 3,534 billion in the first half of 2024[17]. - The company aims to expand its market share in key products such as glutathione injection and flutamide tablets, which hold significant positions in their respective therapeutic fields[17]. - The government continues to emphasize healthcare reforms, including the integration of medical insurance, healthcare, and pharmaceuticals, which may impact the company's operations positively[17]. - The national medical insurance policy adjustments are expected to influence the sales of certain products, necessitating strategic adaptations by the company[17]. - The company is positioned to benefit from ongoing reforms in drug procurement and pricing transparency initiated by the government[17]. - In the first half of 2024, the company's revenue experienced a decline due to industry policy changes, including centralized procurement and adjustments in the medical insurance catalog, impacting sales performance[18]. Subsidiary Performance - The pharmaceutical segment generated revenue of 15,889.13 million yuan, down 11.47% year-on-year, accounting for 49.76% of total revenue[23]. - The net profit for the pharmaceutical segment was -687.87 million yuan, a decrease of 825.52 million yuan compared to the previous year[23]. - Shanghai Fudan Fuhua Pharmaceutical Co., Ltd. reported revenue of 15,843.26 million yuan, a decrease of 11.73% year-on-year, with a net profit of 565.44 million yuan, down 68.74%[23]. - The software segment maintained stability in subsidiaries located in Hefei, Chongqing, Xi'an, and Wuxi, leveraging a team of nearly 900 personnel[22]. - The software segment's revenue was CNY 12.51 million, a decline of 10.29% year-over-year, accounting for 39.19% of total revenue[24]. - The net profit for the software segment dropped by 63.13% to CNY 459.49 million compared to the same period last year[24]. Cash Flow and Liquidity - The cash flow from operating activities showed a net outflow of CNY -51.34 million, a decrease of 561.07% from CNY 11.13 million in the previous year[25]. - The company's cash and cash equivalents decreased by 61.89% to ¥116,415,674.28, mainly due to loan repayments[28]. - The company's total liabilities decreased by 88.73% for non-current liabilities due within one year, amounting to ¥12,500,947.05, mainly due to loan repayments[29]. - The company's cash and cash equivalents decreased from CNY 305,482,145.68 at the beginning of the period to CNY 116,415,674.28 at the end of the period, a reduction of approximately 61.9%[156]. - The company reported a significant decrease in cash received from sales of goods and services, totaling 304,957,449.97 CNY, compared to 382,216,354.29 CNY in the previous year[89]. Environmental Compliance - The company’s subsidiary, Shanghai Fudan Fuhua Pharmaceutical Co., Ltd., is listed as a key pollutant discharge unit, with all pollutants meeting discharge standards[49]. - Wastewater discharge concentrations for various pollutants are significantly below national standards, with ammonia nitrogen at 1.18 mg/L against a limit of 45 mg/L[49]. - The company has equipped its facilities with a complete wastewater collection and treatment system, ensuring that wastewater is treated before being discharged into municipal sewage systems[54]. - The company has installed a 6-ton gas boiler using clean energy, with emissions monitored to comply with standards, including a 12-meter high exhaust stack[60]. - The company has reduced carbon emissions by 260 tons through the implementation of clean energy initiatives, including solar power generation, from January to June 2024[62]. - The company has established a comprehensive environmental emergency response mechanism, including specific plans for hazardous chemical incidents[60]. - The company has received environmental impact assessment approvals for all construction projects, with valid discharge permits until August 2028[55]. Corporate Governance - The company committed to resolving industry competition issues within three years after the completion of the non-compensatory transfer, ensuring no direct or indirect competition with its subsidiaries[64]. - The commitment to maintain the independence of the company includes ensuring that its financial accounting department operates independently and that no funds or resources are misappropriated by controlling shareholders[65]. - The controlling shareholder has pledged to reduce and regulate related party transactions to protect the interests of the company and all shareholders[65]. - The company has established a timeline for the resolution of competition issues, extending the commitment period to September 3, 2025[64]. - The company guarantees that its management team will operate independently and will not hold positions in other enterprises controlled by the shareholder[65]. Legal and Regulatory Matters - The company is involved in significant litigation, including a loan contract dispute with Shanghai Quanchun Industrial Development Co., Ltd. and a construction project dispute with Haimen Fuhua Real Estate Development Co., Ltd.[66]. - The company received a notice from the China Securities Regulatory Commission regarding an investigation into potential violations of information disclosure laws on August 5, 2024[68]. - The integrity status of the company and its major stakeholders remains good during the reporting period[69]. Shareholder Information - The company has a total of 60,895 common shareholders as of the end of the reporting period[73]. - The largest shareholder, Shanghai Fengxian Investment (Group) Co., Ltd., holds 128,338,600 shares, accounting for 18.74% of the total shares[74]. - The company itself holds 17,366,000 shares, which is 2.54% of the total shares[74]. - The company completed a share buyback of 5,365,068 shares, accounting for 0.7836% of the total share capital[75]. Investment and Capital Expenditure - The company has made significant non-equity investments totaling RMB 131,730.70 million, with cumulative actual investment amounting to RMB 149,608.15 million, resulting in a project loss of RMB 1,414.64 million[37]. - The company reported an investment amount of ¥112.50 million during the reporting period, a decrease of 81.17% compared to the previous year[33]. - The company has established multiple subsidiaries focusing on technology development and consulting services across different regions[35]. Accounting and Financial Reporting - The company adheres to the accounting standards set by the Ministry of Finance, ensuring that financial statements reflect true and complete financial conditions[101]. - The company uses RMB as its accounting currency[104]. - The company recognizes revenue based on the fulfillment of performance obligations, either over time or at a point in time, depending on specific criteria being met[144]. - The company recognizes government grants when conditions are met and funds are expected to be received, measured at the amount receivable or fair value[147]. - Deferred tax assets are recognized based on deductible temporary differences, limited to the amount of taxable income expected to offset these differences in future periods[148].

详见公司公告临 2024-035《上海复旦复华科技股份有限公司关于 2024 年上 半年度部分经营数据公告》。 同意 9 票，弃权 0 票，反对 0 票 上海复旦复华科技股份有限公司（以下简称"公司"）于 2024 年 8 月 29 日 以通讯方式召开公司第十一届董事会第五次会议，本次会议的通知和资料已于 2024 年 8 月 19 日发送给全体董事。公司董事会成员 9 名，实际参与表决 9 名， 本次会议的召开符合《公司法》和《公司章程》的有关规定。会议审议通过了如 下事项： 1、上海复旦复华科技股份有限公司 2024 年半年度报告及报告摘要 详见上海证券交易所网站（www.sse.com.cn）。 董事会审计委员会于 2024 年 8 月 29 日召开了 2024 年第六次会议，会议审 议通过了公司《2024 年半年度报告》。审计委员会认为公司《2024 年半年度报告》 中的财务报表已经按照《企业会计准则》的规定编制,在所有重大方面公允反映 了公司 2024 年上半年的财务状况以及 2024 年上半年的经营成果和现金流量。同 意将公司 2024 年半年度报告提交董事会审议。 同意 9 票，弃权 0 票，反 ...

上海复旦复华科技股份有限公司（以下简称"公司"）于 2024 年 8 月 5 日收 到中国证券监督管理委员会（以下简称"中国证监会"）《立案告知书》（编号： 证监立案字 0032024031 号）。因公司涉嫌信息披露违法违规，根据《中华人民共 和国证券法》《中华人民共和国行政处罚法》等法律法规，中国证监会决定对公 司立案。 目前，公司生产经营正常。立案调查期间，公司将积极配合中国证监会的调 查工作，并严格按照相关法律法规的规定和监管要求，及时履行信息披露义务。 公司指定的信息披露媒体为《上海证券报》及上海证券交易所网站 （www.sse.com.cn），有关本公司的信息以本公司在上述指定媒体刊登的公告为 准。敬请广大投资者注意投资风险。 证券代码：600624 证券简称：复旦复华 公告编号：临 2024-033 上海复旦复华科技股份有限公司 关于收到中国证券监督管理委员会 立案告知书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 上海复旦复华科技股份有限公司董事会 2024 年 8 月 6 日 特此公告。 ...

证券代码：600624 证券简称：复旦复华 公告编号：临 2024-032 重要提示： 上海复旦复华科技股份有限公司 关于股票交易风险的提示公告 ●上海复旦复华科技股份有限公司（以下简称"公司"或"本公司"）股票 在 2024 年 7 月 23 日、7 月 24 日、7 月 25 日累计涨幅超 30%，股价短期波动幅 度较大。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 经公司自查，除公司已披露的事项外，截至本公告披露日，公司日常生产经 营及外部环境未发生其他重大变化。 1 （二）重大事项情况 1、经公司自查，并书面征询控股股东上海奉贤投资（集团）有限公司、实 际控制人上海市奉贤区国有资产监督管理委员会，截至本公告披露日，公司、公 司控股股东和实际控制人不存在涉及公司的应披露而未披露的重大信息，包括但 不限于重大资产重组、股份发行、重大交易类事项、业务重组、股份回购、股权 激励、破产重整、重大业务合作、引进战略投资者等重大事项。 ●经公司自查，并书面征询控股股东及实际控制人，截至本公告披露日，确 认不存在应披露而未披 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 上海复旦复华科技股份有限公司（以下简称"公司"）控股子公司海门复华房地 产发展有限公司（以下简称"海门房产"）于 2024 年 7 月 24 日收到了上海仲裁委员 会寄来的（2022）沪仲案字第 1693 号《裁决书》，现将相关情况公告如下： 证券代码：600624 证券简称：复旦复华 公告编号：临 2024-031 上海复旦复华科技股份有限公司 控股子公司涉及仲裁结果的公告 3.对申请人上海泉淳实业发展有限公司的其他仲裁请求不予支持。 以上所述各项应付款项，被申请人海门复华房地产发展有限公司应于本裁决作 出之日起十日内向申请人上海泉淳实业发展有限公司支付完毕。 本裁决为终局裁决。本裁决自作出之日起发生法律效力。 三、本次仲裁对公司本期利润或期后利润等的影响 一、本次仲裁的基本情况 海门房产于 2022 年 7 月 14 日收到了上海仲裁委员会寄来的《关于"（2022）沪 仲案字第 1693 号争议仲裁案"仲裁通知》及仲裁申请书等相关法律文书，上海泉淳 实业 ...

上海市奉贤区国有资产监督管理委员会 上海奉贤投资(集团)有限公司 关于上海复旦复华科技股份有限公司股票交易异常波动的复函 上海复旦复华科技股份有限公司: 你司《关于股票交易异常波动的问询函》收悉，对有关事项回复如下: 截至 2024 年 7 月 24 日收盘,上海奉贤投资(集团)有限公司不存在涉及 你司的应披露而未披露的重大信息，包括但不限于重大资产重组、股份发行、 重大交易类事项、业务重组、股份回购、股权激励、破产重整、重大业务合作、 引进战略投资者等重大事项。 关于上海复旦复华科技股份有限公司股票交易异常波动的复函 上海复旦复华科技股份有限公司: 你司《关于股票交易异常波动的问询函》收悉,对有关事项回复如下: 截至 2024 年 7 月 24 日收盘,上海市奉贤区国有资产监督管理委员会不存 在涉及你司的应披露而未披露的重大信息,包括但不限于重大资产重组、股份 发行、重大交易类事项、业务重组、股份回购、股权激励、破产重整、重大业 务合作、引进战略投资者等重大事项。 上海市奉贤区国有 上海奉贤 ...

证券代码：600624 证券简称：复旦复华 公告编号：临 2024-030 上海复旦复华科技股份有限公司 股票交易异常波动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要提示： ●上海复旦复华科技股份有限公司（以下简称"公司"或"本公司"）股票 在 2024 年 7 月 23 日、7 月 24 日连续两个交易日内收盘价格涨幅偏离值累计超 过 20%，根据《上海证券交易所交易规则》的有关规定，属于股票交易异常波动。 ●经公司自查，并书面征询控股股东及实际控制人，截至本公告披露日，确 认不存在应披露而未披露的重大信息。 2、公司于 2024 年 7 月 18 日披露了《上海复旦复华科技股份有限公司涉及 仲裁的进展公告》，对于田晓丽、李辉、宁波保税区恒昇管理咨询合伙企业(有限 合伙)、上海佰花深处医疗科技有限公司向上海国际经济贸易仲裁委员会（上海 国际仲裁中心）（以下简称"上国仲"）提起的《关于宁波美丽人生医药生物科技 发展有限公司之股权收购协议》争议的仲裁申请，公司提起仲裁反请求申请，上 国仲已受理。由于本次仲裁处 ...

证券代码：600624 证券简称：复旦复华 公告编号：临 2024-029 上海复旦复华科技股份有限公司 股票交易异常波动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要提示： ●上海复旦复华科技股份有限公司（以下简称"公司"或"本公司"）股票 在 2024 年 7 月 17 日、7 月 18 日连续两个交易日内收盘价格涨幅偏离值累计超 过 20%，根据《上海证券交易所交易规则》的有关规定，属于股票交易异常波动。 ●经公司自查，并书面征询控股股东及实际控制人，截至本公告披露日，确 认不存在应披露而未披露的重大信息。 ●公司敬请广大投资者注意二级市场交易风险，理性决策，审慎投资。 一、股票交易异常波动的具体情况 本公司股票在 2024 年 7 月 17 日、7 月 18 日连续两个交易日收盘价格涨幅 偏离值累计超过 20%，根据《上海证券交易所交易规则》有关规定，属于股票交 易异常波动。 二、本公司关注并核实的相关情况 针对公司股票异常波动，本公司对有关事项进行核查，并询问了公司控股股 东、实际控制人。现将有关情 ...

上海市奉贤区国有资产监督管理委员会 关于上海复旦复华科技股份有限公司股票交易异常波动的复函 上海复旦复华科技股份有限公司： 你司《关于股票交易异常波动的问询函》收悉，对有关事项回复如下： 截至 2024 年 7 月 18 日收盘，上海市奉贤区国有资产监督管理委员会不存 在涉及你司的应披露而未披露的重大信息，包括但不限于重大资产重组、股份 发行、重大交易类事项、业务重组、股份回购、股权激励、破产重整、重大业 务合作、引进战略投资者等重大事项。 上海市基 型委员会 上海奉贤投资(集团)有限公司 关于上海复旦复华科技股份有限公司股票交易异常波动的复函 上海复旦复华科技股份有限公司: 你司《关于股票交易异常波动的问询函》收悉，对有关事项回复如下: 截至 2024 年 7 月 18 日收盘,上海奉贤投资(集团)有限公司不存在涉及 你司的应披露而未披露的重大信息，包括但不限于重大资产重组、股份发行、 重大交易类事项、业务重组、股份回购、股权激励、破产重整、重大业务合作、 引进战略投资者等重大事项。 上海奉贤 18日 ...

证券代码：600624 证券简称：复旦复华 公告编号：临 2024-028 上海复旦复华科技股份有限公司 涉及仲裁的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 重要内容提示： 2024 年 7 月 16 日，上海复旦复华科技股份有限公司（以下简称"公司"或"复 旦复华"）收到了上海国际经济贸易仲裁委员会（上海国际仲裁中心）（以下简称"上 国仲"）寄来的《关于<关于宁波美丽人生医药生物科技发展有限公司之股权收购协 议>争议仲裁案事（上国仲（2024）第 1492 号）》，公司对田晓丽、李辉、宁波保税 区恒昇管理咨询合伙企业（有限合伙）、上海佰花深处医疗科技有限公司提起仲裁反 请求申请，上国仲已受理。现将相关情况公告如下： 一、本次仲裁的情况 （一）本次仲裁所涉事项的基本情况 公司于 2024 年 5 月 30 日收到了上国仲寄来的《<关于宁波美丽人生医药生物科 技发展有限公司之股权收购协议>争议仲裁案仲裁通知（上国仲（2024）第 1492 号）》 及仲裁申请书等相关法律文书，田晓丽、李辉、宁波保税区恒昇管理 ...